Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 19/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.61 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.61 |
| ▸ | MC4R | P32245 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8957689 | 0.89 | CFTR (0.62) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| SCHEMBL397939 | 0.88 | CFTR (0.63) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| SCHEMBL394827 | 0.88 | CFTR (0.65) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| SCHEMBL399901 | 0.87 | CFTR (0.73) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| SCHEMBL30492065 | 0.86 | CFTR (0.64) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| SCHEMBL29050127 | 0.86 | CFTR (0.64) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| SCHEMBL396599 | 0.85 | CFTR (0.69) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| SCHEMBL2029166 | 0.85 | CFTR (0.61) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| SCHEMBL397411 | 0.84 | CFTR (0.61) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| SCHEMBL2052432 | 0.84 | CFTR (0.84) | CFTRADORA3ADRB3TBXA2RSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180153874-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-07 | — | — | US | disclosed |
| EP-2502911-B1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMA (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20160318931-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160067239-A9 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2016-03-10 | — | — | US | disclosed |
| US-20160022665-A2 | Pharmaceutical Compositions and Administrations Thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2016-01-28 | — | — | US | disclosed |
| US-20150315186-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-11-05 | — | — | US | disclosed |
| US-20150293078-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED | 2015-10-15 | — | — | US | disclosed |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2015-08-20 | — | — | US | disclosed |
| US-9090619-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150164883-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | VERTEX PHARMA (US) | 2015-06-18 | — | — | US | disclosed |
| US-8188283-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-8101767-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | Vertex Pharmaceuticals Incorported (US) | 2011-04-28 | — | — | US | disclosed |
| US-20100261750-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100184739-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-22 | — | — | US | disclosed |
| US-20090298876-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090246820-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED | 2009-10-01 | — | — | US | disclosed |
| US-20090227797-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-10 | — | — | US | disclosed |
| US-7495103-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184739-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | CFTR 1/4885ADORA3 284/4885ADRB3 290/4885 |
| US-20150164883-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | CFTR, ABCB11, SLC26A4 | CFTR 1/4885ADORA3 790/4885ADRB3 677/4885 |
| US-20180153874-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | CFTR, ABCB11, ABCC5 | CFTR 1/4885ADORA3 1102/4885ADRB3 768/4885 |
| US-20090227797-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CFTR 1/4885ADORA3 284/4885ADRB3 290/4885 |
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | CFTR, SLC26A4, ABCB11 | CFTR 1/4885ADORA3 677/4885ADRB3 495/4885 |
| US-20160022665-A2 | Pharmaceutical Compositions and Administrations Thereof | CFTR, ABCB11, SLC26A4 | CFTR 1/4885ADORA3 790/4885ADRB3 677/4885 |
| US-20090298876-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CFTR 1/4885ADORA3 284/4885ADRB3 290/4885 |
| US-20150315186-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CFTR 1/4885ADORA3 284/4885ADRB3 290/4885 |
| US-20160067239-A9 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | CFTR, ABCB11, ABCC5 | CFTR 1/4885ADORA3 1102/4885ADRB3 768/4885 |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | CFTR 1/4885ADORA3 677/4885ADRB3 495/4885 |
| US-20160318931-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CFTR 1/4885ADORA3 284/4885ADRB3 290/4885 |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | CFTR, ABCB1, ABCC1 | CFTR 1/4885ADORA3 491/4885ADRB3 324/4885 |
| US-20100261750-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, ABCB1, ABCC1 | CFTR 1/4885ADORA3 566/4885ADRB3 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.